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ABSTRACT: The complexity of heparin and heparan sulfate saccharides
makes their puriﬁcation, including many isomeric structures, very challenging
and is a bottleneck for structure−activity studies. High-resolution separations
have been achieved by strong anion exchange (SAX) chromatography on
Propac PA1 and cetyltrimethylammonium (CTA)-C18 silica columns; however,
these entail subsequent desalting methodologies and consequent sample losses
and are incompatible with orthogonal chromatography methodologies and, in
particular, mass spectrometry. Here, we present the CTA-SAX puriﬁcation of
heparin oligosaccharides using volatile salt (VS) buﬀer. In VSCTA-SAX, the use
of ammonium bicarbonate buﬀer for elution improves resolution through both
weaker dissociation and conformational coordination of the ammonium across
the sulfate groups. Using ion mobility mass spectrometry, we demonstrate that
isomeric structures have diﬀerent structural conformations, which makes
chromatographic separation achievable. Resolution of such structures is
improved compared to standard SAX methods, and in addition, VSCTA-SAX provides an orthogonal method to isolate
saccharides with higher purity. Because ammonium bicarbonate is used, the samples can be evaporated rather than desalted,
preventing substantial sample loss and allowing more eﬀective subsequent analysis by electrospray mass spectrometry. We
conclude that VSCTA-SAX is a powerful new tool that helps address the diﬃcult challenge of heparin/heparan sulfate saccharide
separation and will enhance structure−activity studies.
Heparin and heparan sulfate (HS) are part of theglycosaminoglycan (GAG) family of sugars. Heparin
was ﬁrst discovered in 1916 and then later developed into an
anticoagulant-based drug that was ﬁrst used in 1935. Heparin
and HS play an important role in the regulation of biological
systems with chemical synthesis, enzymatic synthesis, and
oligosaccharide puriﬁcation being used to obtain pure
structures to understand structure−function relationships.1−5
Heparin and HS are highly anionic structures with their
synthesis being nontemplate driven with enzymatic speciﬁcity
creating variably sulfated regions and acetylated regions
identiﬁed in HS. Sulfate groups can reside on the 2-O position
of the uronic acid group, and the 6-O, 3-O, and N-position of
the glucosamine with the N-positions also able to adopt an
acetate group and occasionally an amine. It is this micro-
heterogeneity in sulfation that changes between organs,6 stage
of development,7,8 communication, and environment,9 provid-
ing heparin and HS with a dynamic conformational versatility
and thus a vast range of biological functions.10
Size exclusion chromatography (SEC) is often the ﬁrst
method used in heparin/HS oligosaccharide puriﬁcation.11 SEC
separation depends not just on the number of saccharide units
but also on the number of sulfate groups, thus increasing the
likelihood of oligosaccharides with diﬀerent sequences and
structures having equivalent hydrodynamic radii.12 Never-
theless, in isolation of structures ranging from dp4 to dp12,
SEC will separate roughly in dp2 increments due to the
disaccharide cleavage speciﬁcity of various depolymerization
methods.13 Further puriﬁcation of structures isolated by SEC is
most commonly achieved using strong anion exchange (SAX).
SAX is a powerful heparin/HS separation method, as it oﬀers
higher oligosaccharide resolution over other methods currently
available, including hydrophilic interaction chromatography
(HILIC),14 reverse phase ion pairing (RP-IP),15,16 and capillary
electrophoresis (CE).17,18 With small saccharides (for example,
disaccharides), there is a signiﬁcant degree of separation
dependent on the presence of 2OS, 6OS, and NS groups, but as
the oligosaccharide becomes longer, this resolution decreases,19
necessitating the use of additional SAX or orthogonal
chromatography methods.
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Cetyltrimethylammonium SAX (CTA-SAX) is an alternative
SAX method that uses a C8 or C18 column matrix derivatized
with CTA.20,21 The coating of CTA is dynamic, and ﬁne-tuning
of this coat results in the resolution of oligosaccharides
containing up to 20 sulfate groups. The extent of CTA
derivatization is determined by the water−methanol (v/v)
concentration in which the column is derivatized. However, a
drawback of this method arises from the use of the ammonium
methanesulfonic acid mobile phase at pH 2.5 to create the
eluting gradient. This method has not been widely used due to
the diﬃculty in producing the derivatized column, weaker
functional end groups, and acidic elution.
RP-IP chromatography is also used to separate oligosacchar-
ides using di- and tributyl amines.22 All eight disaccharides can
be separated using a tributyl quaternary amine,23 and for larger
oligosaccharides, a triethyl amine is generally used as the ion
pairing agent.24 This method has been employed in the analysis
of sugars from model organisms, such as Caenorhabditis elegans
and Drosophila.25 It has also been used in the compositional
analysis of HS from human tissues, such as liver,26 and in
pharmacokinetics in the analysis of contaminated oral
heparin.27 RP-IP has high resolving capabilities, but removal
of the ion pairing reagent is problematic, resulting in
oligosaccharide losses through desalting and causing in-source
contamination when coupled with a mass spectrometer.
Heparin and HS have polar carboxylates, sulfates, and
hydroxyl groups and are good candidates for the HILIC
technique,28 where HILIC has been used to separate a wide
range of GAG saccharides as well as O- and N-glycans.29−31
Recently, HILIC LC−MS has been used in the analysis of
GAGs from tissues with studies focusing on chondroitin sulfate
(CS)/dermatan sulfate (DS) in connective joint tissues14,32 and
proﬁling heparin and HS33−37 using the parent ion and
collision-induced dissociation (CID) diﬀerences. HILIC uses
volatile buﬀers and is compatible with mass spectrometry but
has low oligosaccharide resolution.
In this paper, we describe an ammonium-based (volatile salt)
CTA-SAX method in conjunction with SEC and conventional
SAX that provides improved separation of isomeric heparin
oligosaccharides. The puriﬁcation of heparin oligosaccharides
using the VSCTA-SAX method avoids the need for desalting
and improves column resolution, and the products are directly
compatible with mass spectrometry analysis.
■ EXPERIMENTAL METHODS
Materials and Reagents. All chemicals of analytical or
HPLC-grade purity were purchased from Sigma (Gillingham,
UK) and VWR (Lutterworth, UK) unless otherwise stated.
Disaccharide standards 1−8 were purchased from Iduron
(Manchester, UK). Heparin was purchased from Alfa Aesar
(Massachusetts, USA). Heparinase I−III enzymes were
purchased from IBEX (Canada).
Disaccharide CTA-SAX Chromatography. CTA-SAX
was performed based on the method of Mourier and Viskov
(2004)20 utilizing a Discovery C18 silica column (250 × 4.6
mm, 5 μm; Supelco), which was derivatized with 1 mM
cetyltrimethylammonium in a water:methanol ratio of 50:50
(v/v). Separations were performed using a Shimadzu SPD 10A
instrument using a UV−visible spectrophotometric detector.
Eluent A was HPLC grade water, pH 3, using methanesulfonic
acid, and eluent B was ammonium methanesulfonic acid (2 M),
pH 2.5. The elution proﬁles were monitored by absorbance at
232 nm. Eight commonly occurring authentic HS disaccharides
(Dextra Laboratories) were injected and eluted with a 0−50%
linear gradient of eluent B at a ﬂow rate of 1 mL/min over 60
min. The disaccharide separation was repeated using HPLC
grade water as eluent A and 2 M ammonium bicarbonate as
eluent B.
Digestion of Heparin. Heparin (1 g) was dissolved in 500
μL of lyase buﬀer (100 mM sodium acetate, 10 mM calcium
acetate) and digested into oligosaccharide products using 1 mU
of heparinase I (1 mU per 1 μL) to 10 mg of heparin at 37 °C.
At 2, 3, 4, 6, and 8 h, a 120 μL aliquot was taken from the
reaction and quenched by denaturing the heparinase enzyme at
98 °C for 3 min. The resulting products were pooled and
further separated as described below.
Size Exclusion Chromatography (SEC). Heparin was
separated using a Biorad Econo column packed in-house with
prep grade Sephadex 30 beads (15 mm x 170 cm, bead size 34
μm; GE Healthcare) on a Delta 600 HPLC system (Waters). A
500 mg sample of the pooled digested heparin was made up to
1 mL with 0.5 M ammonium bicarbonate and injected into the
system. The digested heparin sample was eluted using 0.5 M
ammonium bicarbonate with a ﬂow rate of 0.1 mL/min. The
elution proﬁle was monitored with absorbance at 232 nm.
Fractions were pooled and repeatedly freeze-dried using water
until all the ammonium bicarbonate was removed.
Strong Anion Exchange Chromatography (SAX). SEC
fractions were separated using a Propac PA1 column (4.6 mm
× 250 mm, 5 μm bead size; Thermo Scientiﬁc) on a Delta 600
HPLC system (Waters). Eluent A was HPLC grade water, and
eluent B was 2 M NaCl. The concentration of each
oligosaccharide fraction loaded was dependent on its previous
puriﬁcation method, as stated in the text. The initial
hexasaccharide separation was performed on a 0−1.4 M NaCl
gradient over 90 min using the Propac PA1 column.
Subsequent bespoke elution gradients for each oligosaccharide
were calculated based on the ﬁrst round of SAX separation.
Isolated peaks were collected and subjected to further
orthogonal techniques.
Oligosaccharide VSCTA-SAX Chromatography. The
C18 column (4.6 mm × 250 mm, 5 μm bead size; Sigma)
was derivatized with 1 mM cetyltrimethylammonium in a
water:methanol ratio of 40:60 (v/v). Oligosaccharides collected
from the Propac PA1 SAX column separation were diluted 1 in
10, and multiple injections were performed to load the entire
sample onto the VSCTA-SAX column. VSCTA-SAX separa-
tions were performed using a Waters Delta 600 HPLC with a
UV−visible spectrophotometric detector. Eluent A was HPLC
grade water, and eluent B was 2 M ammonium bicarbonate
using a ﬂow rate of 1 mL/min at a temperature of 40 °C. The
elution proﬁles were monitored with an absorbance at 232 nm.
Gradient details for each sample are in the text and ﬁgure
legends. Each fraction was dried on a SPD121B speed vac
(Thermo Scientiﬁc) prior to mass spectrometry and composi-
tional analysis.
Disaccharide Compositional Analysis. Puriﬁed oligosac-
charide structures were digested using 10 μL of 1 mU/1 μL,
heparinase I, heparinase II, and heparinase III. Each reaction
was incubated at 30 °C for 24 h to achieve complete digestion.
The resulting disaccharide products were then separated on a
SAX Propac PA1 (4.6 mm × 250 mm, 5 μm bead; Dionex)
column using a Waters Delta 600 HPLC with a UV−visible
spectrophotometric detector. Each sample was separated on a
0−1 M NaCl gradient over 60 min. Elution proﬁles were
monitored with an absorbance of 232 nm. Disaccharide
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standards (1 μg of each standard) were loaded onto the same
SAX Propac PA1 column and separated using the same
gradient, so that the samples could be compared.
Ion Mobility-Mass Spectrometry (IM-MS) of Isomeric
Hexasaccharides. IM-MS was performed on a Synapt G1
mass spectrometer equipped with a T-wave mobility cell
(Waters Corp.). Sample concentration was calculated based on
its 232 nm absorbance and then adjusted to a concentration of
0.5 μM in water/acetonitrile (50:50 v/v) with 500 mM
ammonium hydroxide. The borosilicate tips were made in-
house as stated in previous publications.38,39 Oligosaccharides
were sprayed in a borosilicate gold-coated tip, and mass spectra
were acquired in negative ion mode with a capillary voltage of
0.55 kV, a sample cone voltage of 7 V, and an extraction cone
voltage of 0.6 V. The ion mobility parameters for each tetra- or
hexasaccharide can be found in the Supporting Information.
MS/MS was performed on selected ions and collisionally
activated at 15 and 20 V in the transfer cell with the mobility
cell turned oﬀ to produce comparable CID data for each
isomer.
■ RESULTS AND DISCUSSION
Disaccharide Analysis by CTA-SAX Employing Volatile
Buﬀers. The natural diversity of heparin and HS provides a
rich source for structure−function studies, but many
oligosaccharides are isomeric structures, making puriﬁcation
diﬃcult. This arises from the structures having identical
negative charge and is compounded as the chain length
increases.12,40 The separation problems deepen due to the
molecule being linear and the distance between the groups
being close.41,42 As the number of adjacent negative charges
increases, the charge−charge repulsion makes this task even
more diﬃcult. Low pH buﬀers (e.g., pH 1) result in
protonation of 50% of the sulfate groups and 99% of the
carboxylic acid groups, potentially altering conformation and
interaction with columns. At neutral pH, most sulfate groups
will be negatively charged, causing charge−charge repulsion as
well as adduct retention. It is known that coordination of salts
causes diﬀerent structural conformations,43 so here we used
ammonia-based salts to enhance the level of diversity for
isomeric separation. The other major obstacle for puriﬁcation is
the use of nonvolatile salt buﬀers, which necessitates
subsequent desalting methods that for hydrophilic HS
oligosaccharides result in interactions and material loss (with
desalting column recoveries of only 60−70% observed
compared to >90% recovery with VSCTA-SAX; data not
shown). Nonvolatile salts also aﬀect mass spectrometry analysis
by increasing the number of adducts attached to the sulfate
groups and via signal suppression. We reasoned that the use of
a volatile salt SAX method would overcome these problems. A
conventional SAX method using a Propac PA1 column was
tested with volatile ammonium bicarbonate salts; however,
neither disaccharides nor oligosaccharides eluted from the
column, indicating the interaction was too strong for
ammonium bicarbonate to achieve eﬀective dissociation (data
not shown). To overcome this, we investigated CTA-SAX19 in
which a C-18 reverse phase column is ﬁrst derivatized using
CTA, imparting a positive charge on the matrix and allowing
the column to be used for SAX. First, eight commonly
occurring HS disaccharide standards were separated on CTA-
SAX using a 0−1 M ammonium methanesulfonic acid gradient
over 60 min (Figure 1a). All disaccharides eluted with baseline
resolution; furthermore, the column separated α and β anomers
for the disaccharides, resulting in double peaks for many of the
standards. The standards were then separated on the CTA-SAX
column using the volatile ammonium bicarbonate salt (Figure
1b). As with the ammonium methanesulfonic acid, all eight
disaccharides were separated but without separation of the
anomeric structures with the minor drawback of increased
baseline absorbance. The ability of the ammonium bicarbonate
to dissociate disaccharides from the CTA-SAX column but not
the Propac PA-1 column suggested that the VSCTA-SAX
system might be ideal as an additional puriﬁcation step for
oligosaccharides.
Major and Minor Oligosaccharide Peak Separation.
To prove the eﬀectiveness of VSCTA-SAX to prevent losses,
improve separation, and increase compatibility with other
techniques such as mass spectrometry, we isolated a heparin
hexasaccharide using traditional SEC and SAX followed by
VSCTA-SAX and determined its sequence using mass
spectrometry. Full length heparin was digested with heparinase
I, and the oligosaccharide mixture (ranging from dp2 to dp30)
was separated using SEC (data not shown). The dp6
oligosaccharide fraction isolated from SEC separation was
subjected to further chromatographic separation using Propac
PA1 SAX (Figure 2). Separation of the dp6 SEC fraction is
shown in Figure 2; peaks A−C were selected for further
Figure 1. CTA-SAX separation of HS standards using nonvolatile and
volatile buﬀers. Disaccharide standards were injected and eluted from
CTA-derived Discovery C18 column using a 0−1 M gradient over 60
min of (a) ammonium methanesulfonic acid, pH 2.5 and (b)
ammonium bicarbonate. Standards: 1, ΔUA-GlcNAc; 2, ΔUA-GlcNS;
3, ΔUA-GlcNAc6S; 4, ΔUA2S-GlcNAc; 5, ΔUA-GlcNS6S; 6,
ΔUA2S-GlcNS; 7, ΔUA2S-GlcNAc6S; 8, ΔUA2S-GlcNS6S.
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puriﬁcation. Previous work has focused on using such partially
resolved SAX fractions.44
Peak A was separated further using a Propac PA1 column
employing a shallower salt elution gradient to improve
oligosaccharide resolution (Figure 3a). However, using this
gradient, full oligosaccharide separation could not be obtained.
Peak D from this run was then further separated by VSCTA-
SAX chromatography using ammonium bicarbonate as the
elution buﬀer, demonstrating resolution of two separate
oligosaccharide structures (Figure 3b). The reasons for these
two peaks being separated could be related to the spacing of the
CTA linker on the column or because an ammonium salt is
weaker in its displacement than a sodium salt. It could also be
because ammonium ions are known to coordinate and separate
oligosaccharides diﬀerently than sodium adducts as shown
through graphite LC−MS (Miller, Karlsson, and Turnbull;
unpublished data). The larger peak, peak E (Figure 3b), was
selected for mass spectrometry analysis and compositional
analysis to determine whether the structure was pure and
establish whether it could be sequenced (Figure 3c−e). MS
showed that this peak was pure with an m/z 509.9 [M − 3H]3−,
which corresponds to a hexasaccharide with six sulfates and one
acetyl group (dp6 + 6SO3 + 1Ac; Figure 3c). Data from tandem
mass spectrometry and compositional analysis were both used
to inform sequencing (Figure 3d and e).45−48 Compositional
analysis of peak E (Figure 3e) showed that this structure
contains three diﬀerent disaccharides: ΔUA-GlcNAc6S,
ΔUA2S-GlcNS, and ΔUA2S-GlcNS6S. The order of the
disaccharides can be determined based on the acetate group,
as this does not dissociate in the mass spectrometer and
displays a distinct mass signature compared to sulfate groups.
The ions m/z 486 (Y3, UA-GlcNAc6S-UA2S-GlcNS), 429.7
(C5, ΔUA2S-GlcNS6S-UA-GlcNAc6S-UA2S), and 636 (B5,
ΔUA2S-GlcNS6S-UA-GlcNAc6S-UA2S) show that the
GlcNAc is positioned in the middle of the structure and that
the GlcNS is at the reducing terminal. If the GlcNAc residue
was the reducing terminal disaccharide, it would be expected
that ions corresponding to m/z 536 (C4), 615 (B5), and 624
(C5) would be observed; none of these ions were observed in
the product ion spectra. Therefore, the sequence can be deﬁned
as ΔUA2S-GlcNS6S-UA-GlcNAc6S-UA2S-GlcNS (Figure S-
1).
Separation of Isomeric Structures. The majority of
structures within heparin and HS have multiple isomers due to
variation in positioning of sulfate and acetate groups in diﬀerent
saccharides of the same mass, making isolation of single
structures challenging. For example, peak B (Figure 2) clearly
contains multiple species and has peak shoulders and therefore
likely represents multiple oligosaccharide structures. For
tackling this problem, the middle peak was collected with the
aim of isolating the major product with only minor overlapping
products. Peak B (Figure 2) was separated a second time using
the SAX column with a shallower gradient (0.6−1.1 M NaCl
over 60 min) in an eﬀort to improve its separation (Figure 4a).
In this case, a greater level of separation was observed. It is
likely that the resolving power of these peaks could be further
enhanced by using a shallower salt gradient and reduced sample
loading. Because the resulting major peak (peak F) was not
baseline resolved, as commonly observed for heparin/HS
oligosaccharides,11 there is a need to have additional orthogonal
separation methodologies. To avoid desalting and consequent
losses, peak F (containing a high concentration of NaCl) was
loaded onto the VSCTA-SAX column through dilution and
multiple injections. Peak F oligosaccharide structures were then
eluted from the VSCTA-SAX column with a 0.7−1.4 M
ammonium bicarbonate gradient (Figure 4b). This method of
separation resulted in close to baseline resolution of four
apparent oligosaccharide compounds, demonstrating the
enhanced resolution of VSCTA-SAX chromatography. The
ammonium bicarbonate salt was readily removed via centrifugal
evaporation (data not shown). Peaks G and H were analyzed by
oﬄine ESI-MS. They both displayed an m/z of 549.3,
conﬁrming that they were mass isomers as anticipated and
correspond to a dp6 with 8SO3 (Figure 4c). Furthermore, IM-
MS of peaks G and H revealed that they displayed diﬀerent
arrival time distributions (ATDs) of 3.39 and 3.67 ms,
respectively (Figure 4d). This suggests diﬀerent structural
conformations with peaks G and H displaying more compact
and extended conformations, respectively. Because both
compounds could be separated though a charge-dependent
interaction method, this result indicates that this separation is at
least partly dependent on their diﬀerent conformational
properties.
For the structure of the isolated peaks to be determined
further, tandem mass spectrometry and compositional analysis
were performed on both peaks G and H. MS revealed very
diﬀerent product ion spectra (Figure 4e). Compositional
analysis showed that peak G contained a single ΔUA-GlcNS6S
and two ΔUA2S-GlcNS6S disaccharides, whereas peak H
contained one ΔUA2S-GlcNS and two ΔUA2S-GlcNS6S
(Figure 4f). Because there are two ΔUA2S-GlcNS6S, the ﬁrst
piece of information to identify in the product ion spectra is
whether these disaccharides are adjacent. In peak G, no doubly
charged 576 product ion was observed (Figure 4e), whereas in
peak H, a doubly charged 576 product ion was observed,
indicating that the two trisulfated disaccharides must be
adjacent. Therefore, the sequence of peak H is ΔUA2S-
GlcNS-UA2S-GlcNS6S-UA2S-GlcNS6S or ΔUA2S-GlcNS6S-
UA2S-GlcNS6S-UA2S-GlcNS (Figures S-1 and S-2). In
contrast, peak G has a major triply charged product ion of
464 corresponding to Z4 (GlcNS6S-UA-GlcNS6S-UA2S-
GlcNS6S). The Y3 ion (UA-GlcNS6S-UA2S-GlcNS6S) and
Y2 ion (GlcNS6S-UA2S-GlcNS6S) conﬁrmed that the UA-
Figure 2. SAX separation of a heparin hexasaccharide mixture. The
dp6 oligosaccharide fraction isolated from SEC (data not shown) was
collected and separated using a Propac PA1 SAX column on a 0−1.4
M NaCl gradient over 90 min as described in the Experimental
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GlcNS6S is in the middle of the oligosaccharide structure
(Figure 4e). Therefore, the sequence of the oligosaccharide
isolated from peak G is ΔUA2S-GlcNS6S-UA-GlcNS6S-UA2S-
GlcNS6S (Figures S-1 and S-2).
In a further demonstration of the utility of VSCTA-SAX
chromatography, we were also able to separate another three
hexasaccharides (dp6 + 8SO3) from the same dp6 SEC fraction
(peak C; Figure 2). This peak was further separated on a
shallow gradient (0.84−1.2 M NaCl over 60 min) on a SAX
Propac PA1 column (Figure 5a). The structures were separated
into two peaks, I and J (although not to baseline resolution),
and were collected separately. It should be noted that collecting
partial peaks and reseparating on a shallower gradient can also
lead to improved resolving power. Peaks I and J were both
subjected to separation on the VSCTA-SAX column with a
0.8−1.5 M ammonium bicarbonate gradient. This resulted in
Figure 3. Puriﬁcation of minor and major oligosaccharide products using SAX and VSCTA-SAX. (a) SAX separation of peak A on a Propac PA1
SAX column using a 0.6−1.1 M NaCl gradient over 60 min. (b) Peak D was separated further using a VSCTA-SAX column on a 0.7−1.4 M
ammonium bicarbonate gradient B in A over 60 min. (c) MS of peak E showing an m/z of 509.9, which corresponds to dp6 + 6SO3 + 1Ac. (d) MS/
MS of peak E at 15 and 20 V. (e) Disaccharide analysis of peak E. The lower chromatograms correlate to disaccharide standards. The upper trace is
disaccharide analysis of peak E. This information deﬁned the structure with an overall sequence of ΔUA2S-GlcNS6S-UA-GlcNAc6S-UA2S-GlcNS.
Standards: 3, ΔUA-GlcNAc6S; 4, ΔUA2S-GlcNAc; 5, ΔUA-GlcNS6S; 6, ΔUA2S-GlcNS; 7, ΔUA2S-GlcNAc6S; 8, ΔUA2S-GlcNS6S.
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improvements in peak resolution (Figure 5b and c). MS
showed that all three structures had the same m/z ratio of 549.3
[M − 3H]3− (data not shown). It was particularly noteworthy
that IM-MS on these three isomeric structures revealed that
each structure had diﬀerent ATDs. Peak K displayed the most
extended conformation with an ATD of 3.74 ms, peak M a
slightly more compact conformation (3.60 ms), and peak L a
much more compact structural conformation (3.46 ms) (Figure
5d). MS/MS and compositional analysis were completed on all
three of these structures (Figure 5e and f). Compositional
Figure 4. Puriﬁcation and analysis of isomeric heparin hexasaccharide products from peak B (Figure 2) using SAX and VSCTA-SAX. (a) SAX
separation of peak B on a Propac PA1 SAX column using a 0.6−1.1 M NaCl gradient over 60 min. (b) Peak F was separated further using a VSCTA-
SAX column on a 0.7−1.4 M ammonium bicarbonate gradient over 60 min. (c) MS of peaks G and H displayed an m/z of 549.3, which corresponds
to dp6 + 8SO3. (d) IM-MS of peaks G and H. (e) MS/MS of peaks G and H at 15 V. (f) The lower chromatogram correlates to disaccharide
standards, and the upper two chromatograms correlate to disaccharide analysis of peaks G and H. This information gave peak G an overall sequence
of ΔUA2S-GlcNS6S-UA-GlcNS6S-UA2S-GlcNS6S and peak H a sequence of ΔUA2S-GlcNS-UA2S-GlcNS6S-UA2S-GlcNS6S. Standards: 3, ΔUA-
GlcNAc6S; 4, ΔUA2S-GlcNAc; 5, ΔUA-GlcNS6S; 6, ΔUA2S-GlcNS; 7, ΔUA2S-GlcNAc6S; 8, ΔUA2S-GlcNS6S.
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analysis showed that peaks K and L each contained one ΔUA-
GlcNS6S and two ΔUA2S-GlcNS6S disaccharides, whereas
peak M contained one ΔUA2S-GlcNS and two ΔUA2S-
GlcNS6S disaccharides. MS/MS of these structures showed
that all three contained a doubly charged product ion of 576
corresponding to an intact dp4 + 6SO3 (UA2S-GlcNS6S-
UA2S-GlcNS6S). Thus, the sequences of peaks K and L are
deﬁned as ΔUA-GlcNS6S-UA2S-GlcNS6S-UA2S-GlcNS6S and
Figure 5. Separation of three isomeric structures. (a) Propac PA1 SAX separation of peak C on a 0.84−1.2 M NaCl gradient over 60 min. (b)
VSCTA-SAX separation of peak I on a 0.8−1.5 M ammonium bicarbonate gradient over 60 min, isolating peak K. (c) VSCTA-SAX separation of
peak J on a 0.8−1.5 M ammonium bicarbonate gradient over 60 min, isolating peaks L and M. (d) IM-MS separation of peaks K−M. (e) MS/MS of
peaks K−M at 15 V. (f) The lower chromatogram correlates to disaccharide standards, and the upper three chromatograms correlate to disaccharide
analysis of peaks K−M. The sequence of peak K is ΔUA-GlcNS6S-UA2S-GlcNS6S-UA2S-GlcNS6S, peak L is ΔUA2S-GlcNS6S-UA2S-GlcNS6S-
UA-GlcNS6S, and peak M is ΔUA2S-GlcNS6S-UA2S-GlcNS6S-UA2S-GlcNS. Standards: 3, ΔUA-GlcNAc6S; 4, ΔUA2S-GlcNAc; 5, ΔUA-
GlcNS6S; 6, ΔUA2S-GlcNS; 7, ΔUA2S-GlcNAc6S; 8, ΔUA2S-GlcNS6S.
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ΔUA2S-GlcNS6S-UA2S-GlcNS6S-UA-GlcNS6S, respectively,
and the sequences of peaks M and H are ΔUA2S-GlcNS6S-
UA2S-GlcNS6S-UA2S-GlcNS or ΔUA2S-GlcNS-UA2S-
GlcNS6S-UA2S-GlcNS6S, respectively (Figure S-1). These
two structures with identical compositional analysis but
disaccharide UA-GlcNS6S at either the reducing end or the
nonreducing end displayed the largest ATD diﬀerence (3.74
and 3.46 ms). This suggests that oligosaccharide conformation
can have an eﬀect on separations using SAX columns, possibly
via the diﬀerent distribution of free electrons aﬀecting the
strength of the interaction.
■ CONCLUSIONS
Here, we demonstrate the isolation, separation, and analysis of
multiple hexasaccharide structures from heparin oligosaccharide
starting material. The VSCTA-SAX methodology we describe
resulted in enhanced resolution compared to previous methods,
likely resulting from a combination of the weaker displacement
salt, the coordination of ammonium with the sulfate groups,
and diﬀerences in structural conformation and electron
distribution. We have demonstrated that VSCTA-SAX provides
improved separation of structural isomers compared to that of
HILIC and RP-IP and also removes the need for traditional
desalting methods. Volatile salt methods for heparin/HS
chromatography techniques are increasingly in demand to
improve yields, which is crucial because only very small
amounts of individual structures are often puriﬁed from
complex starting mixtures. Thus, the practicality of subsequent
analysis and screening is enhanced using VSCTA-SAX. We
demonstrate here that the combination of established SEC and
SAX separation techniques with VSCTA-SAX allowed the
separation of ﬁve isomeric structures (dp6 + 8SO3) and their
sequence determination in a manner not possible with
traditional methods alone. We have also applied the method
to puriﬁcation of isomeric heparin saccharides for studying
selectivity of interactions with the chemokine MCP-1/CCL2.49
We conclude that VSCTA-SAX is a powerful additional tool to
enhance structure−activity studies on heparin/HS saccharides.
■ ASSOCIATED CONTENT
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The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.anal-
chem.6b02801.
Figure S-1, structural representation of each sequenced
heparin saccharide; Figure S-2, workﬂow procedure
involving the puriﬁcation and sequencing of oligosac-
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